Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Trulicity is frequently among the more affordable GLP-1 imports reaching Pakistan. That makes it attractive to anyone comparing monthly figures.
The problem is what you get for the money. Trulicity is a diabetes medication, and its weight loss effect is roughly three kilograms.
What Trulicity is
Trulicity is dulaglutide, made by Eli Lilly, injected once weekly at 0.75 mg, 1.5 mg, 3.0 mg or 4.5 mg.
It is approved for type 2 diabetes, not for weight management. Any use purely for weight loss is off-label.
That distinction matters commercially as well as clinically. Diabetes drugs are frequently priced lower than weight management drugs in their source markets, and that difference carries through to import cost. Part of why Trulicity looks cheap here is that it is a diabetes product.
The weight arithmetic
In SUSTAIN 7, published in Lancet Diabetes and Endocrinology, dulaglutide 1.5 mg produced 3.0 kg of weight loss over 40 weeks. Semaglutide 1.0 mg produced 6.5 kg in the same trial.
At the lower doses, dulaglutide 0.75 mg produced 2.3 kg against semaglutide 0.5 mg at 4.6 kg.
Higher dulaglutide doses of 3.0 mg and 4.5 mg were approved later and produce somewhat more, though they narrow rather than close the gap.
Set against the field:
| Drug | Weight result |
|---|---|
| Tirzepatide 15 mg | 20.9 percent |
| Semaglutide 2.4 mg | 14.9 percent |
| Liraglutide 3.0 mg | 8.4 kg |
| Dulaglutide 1.5 mg | ~3 kg |
If you weigh 90 kg, semaglutide's 14.9 percent is roughly 13 kg. Dulaglutide's 3 kg is a fifth of that.
Why cheaper is not better value
The honest way to assess this is cost per kilogram lost rather than cost per month.
Suppose Trulicity costs meaningfully less per month than semaglutide. If it produces less than a quarter of the weight loss, you are paying less to achieve much less, and the cost per kilogram is worse.
You would also be taking it for the same duration, attending the same consultations, paying the same cold-chain delivery costs and running the same supply interruption risks.
Spending less on a treatment that does not get you where you want to be is not a saving. It is a smaller expenditure with a smaller return, and frequently a worse ratio.
What Trulicity genuinely does better
Two things, and they are real.
The injection device. Trulicity's pen has a hidden, pre-attached needle. You do not attach anything, dial anything or see a needle. You press it against your skin and push a button.
For someone with genuine needle anxiety, this is not a minor convenience. A medication you will actually inject every week beats a stronger one you avoid. This is a legitimate reason to choose it.
Cardiovascular evidence. The REWIND trial followed 9,901 people with type 2 diabetes over a median 5.4 years and found reduced major adverse cardiovascular events, with most participants not having established cardiovascular disease at enrolment. That is unusually long follow-up and it matters for someone managing diabetes with cardiovascular risk.
Neither of those advantages is about weight.
The cost picture
Trulicity is not registered in Pakistan. There is no approved local supply and no regulated price.
Imported GLP-1 injections generally run Rs 20,000 to Rs 50,000 per month, with dulaglutide typically toward the lower end.
The costs beyond the pen are the same as every injectable here. Physician consultation at roughly Rs 2,000 to Rs 5,000 at private clinics, cold-chain delivery since dulaglutide requires refrigeration, baseline and periodic blood work, and the ever-present risk of supply interruption breaking a course.
Escalation is simpler than tirzepatide's. Trulicity starts at 0.75 mg and can increase to 1.5 mg after four weeks, so you reach a stable dose and stable cost quickly.
Who should actually consider it
Someone with type 2 diabetes, particularly with cardiovascular risk factors, for whom REWIND's evidence is directly relevant and weight loss is a welcome secondary benefit.
Someone with significant needle anxiety who would not sustain treatment with a more complex device.
Someone who has tolerated dulaglutide well and has no reason to change.
For weight loss specifically, in someone without diabetes, it is difficult to justify. You would be using a diabetes drug off-label, at doses never designed for weight management, achieving roughly 3 kg, while carrying every cost and risk that comes with imported injectables in this market.
The honest alternative framing
If cost is the constraint that pushed you toward Trulicity, the useful question is not which injectable is cheapest. It is what you can obtain continuously and verify.
METASLIM™ physician-reviewed drops address that differently. Registration with the national regulator can be checked rather than taken on trust. Sublingual delivery removes the cold chain and the needle entirely. A physician reviews every order before dispatch, included in the programme rather than charged separately.
It is not dulaglutide and does not treat diabetes. Anyone managing diabetes should be making medication decisions with their treating doctor, and no supplement substitutes for prescribed glucose control. What it addresses is appetite, which is the mechanism a 3 kg diabetes-dose drug does not meaningfully change.
Our page on the doctor-guided approach covers what that review involves. Our full guide to dulaglutide covers the drug in detail, and the monthly cost comparison sets every option side by side.
The summary
Trulicity is often among the cheaper GLP-1 imports because it is a diabetes drug rather than a weight management one.
It produces roughly 3 kg of weight loss, against 6.5 kg for semaglutide in the same head-to-head trial and far more at weight-management doses.
Lower monthly cost for a fifth of the result is worse value per kilogram, not better.
Its real advantages are the easiest injection device in the class and strong long-term cardiovascular evidence from REWIND, neither of which relates to weight.
It is not registered in Pakistan.
See the current program price for a locally registered comparison.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.